Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of Liproca Depot in localized prostate cancer patients on active surveillance
2016-002504-43Phase 2Completed
- Sponsor
- LIDDS AB
- Start
- Oct 2016
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-blind trial of 2-hydroxyflutamide depot in prostate cancer (PCa), sponsored by LIDDS AB. Primary endpoint: Safety and tolerability of a single Liproca Depot injection. Started Oct 2016; status: completed.
02
Drugs
2-hydroxyflutamide depot
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-002504-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002504-43.